PDCD1 and melanoma: Following the first clinically used ICI, the CTLA-4 inhibitor ipilimumab, has been approved for the treatment of advanced melanoma, PD-1 inhibitors and PD-L1 inhibitors have also been shown to significantly prolong survival of melanoma [13,14].